FDA approves Lilly breast cancer med for expanded use
The U.S. Food and Drug Administration have approved expanded use of Eli Lilly’s Verzenio (abemaciclib) breast cancer drug when used as an initial treatment for certain women with advanced or metastatic disease.
The oral drug, which competes with Pfizer’s Ibrance and Novartis's Kisqali, was originally approved last September in combination with AstraZeneca’s Faslodex (fulvestrant).
The latest approval comes after a late-stage study that found the Lilly drug, when taken twice daily with anastrozole or letrozole significantly delayed disease progression.
Read the Reuters report